Shopping Cart 0
Cart Subtotal
USD 0

Arbor Pharmaceuticals LLC - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Arbor Pharmaceuticals LLC (Arbor) is a specialty pharmaceutical company that offers prescription and generic products. The company offers medicines in the therapeutic areas of cardiology, pediatrics, and neuroscience, generics, and hospital and specialty markets. Its lead products under phase 3 stage include AR06, AR19 and AR25; and under phase 1 stage includes AR20. The company's partnered products under phase1 stage include AR29 and AR30; and under phase 3 stage includes AR28. It also provides licensing, manufacturing, development and commercialization of late-stage prescription products. Arbor also develops both new chemical entities and already approved molecules for new indications or in improved dosage forms. The company offers products, which are used in treatment areas such as cardiovascular, emergency, pediatrics, psychiatry, oncology, dermatology, urology, and endocrinology diseases. The company markets its products through sales professionals to hospitals and physicians across the US. Arbor is headquartered in Atlanta, Georgia, the US.

Arbor Pharmaceuticals LLC-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deal Details 11

Asset Purchase 11

Arbor Pharma To Acquire US Rights For Gliadel Wafer From Eisai 11

Venture Financing 13

XenoPort Raises USD20 Million in Venture Financing 13

Private Equity 14

KKR to Acquire Minority Stake in Arbor Pharma 14

Partnerships 15

Debiopharm Enters into Distribution Agreement with Arbor Pharma 15

Licensing Agreements 16

Dr. Reddy's Labs Enters into Licensing Agreement with XenoPort for XP23829 16

Reckitt Benckiser Pharma Enters Into Licensing Agreement With XenoPort For Arbaclofen Placarbil 17

Takeda Pharma Enters Into Licensing Agreement With Arbor Pharma For Edarbi And Edarbyclor 18

Equity Offering 19

XenoPort Files Shelf Registration Statement for Public Offering of Shares For USD150 Million 19

XenoPort Completes Public Offering Of Shares For USD 85.8 Million 20

XenoPort Completes Public Offering Of Common Stock For USD 46 Million 21

Debt Offering 22

XenoPort Raises USD115 Million in Private Placement of 2.5% Notes Due 2022 22

Acquisition 24

Arbor Pharma Acquires Shares of XenoPort in a Tender Offer 24

Arbor Pharmaceuticals LLC-Key Competitors 26

Arbor Pharmaceuticals LLC-Key Employees 27

Arbor Pharmaceuticals LLC-Locations And Subsidiaries 28

Head Office 28

Other Locations & Subsidiaries 28

Appendix 29

Methodology 29

About GlobalData 29

Contact Us 29

Disclaimer 29


List Of Figure

List of Figures

Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Key Facts 2

Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Arbor Pharmaceuticals LLC, Deals By Therapy Area, 2012 to YTD 2018 8

Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Arbor Pharma To Acquire US Rights For Gliadel Wafer From Eisai 11

XenoPort Raises USD20 Million in Venture Financing 13

KKR to Acquire Minority Stake in Arbor Pharma 14

Debiopharm Enters into Distribution Agreement with Arbor Pharma 15

Dr. Reddy's Labs Enters into Licensing Agreement with XenoPort for XP23829 16

Reckitt Benckiser Pharma Enters Into Licensing Agreement With XenoPort For Arbaclofen Placarbil 17

Takeda Pharma Enters Into Licensing Agreement With Arbor Pharma For Edarbi And Edarbyclor 18

XenoPort Files Shelf Registration Statement for Public Offering of Shares For USD150 Million 19

XenoPort Completes Public Offering Of Shares For USD 85.8 Million 20

XenoPort Completes Public Offering Of Common Stock For USD 46 Million 21

XenoPort Raises USD115 Million in Private Placement of 2.5% Notes Due 2022 22

Arbor Pharma Acquires Shares of XenoPort in a Tender Offer 24

Arbor Pharmaceuticals LLC, Key Competitors 26

Arbor Pharmaceuticals LLC, Key Employees 27

Arbor Pharmaceuticals LLC, Subsidiaries 28

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Arbor Pharmaceuticals LLC, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Arbor Pharmaceuticals LLC (Arbor) is a specialty pharmaceutical company that offers prescription and generic products. The company offers medicines in the therapeutic areas of cardiology, pediatrics, and neuroscience, generics, and hospital and specialty markets. Its lead products under phase 3 stage include AR06, AR19 and AR25; and under phase 1 stage includes AR20. The company's partnered products under phase1 stage include AR29 and AR30; and under phase 3 stage includes AR28. It also provides licensing, manufacturing, development and commercialization of late-stage prescription products. Arbor also develops both new chemical entities and already approved molecules for new indications or in improved dosage forms. The company offers products, which are used in treatment areas such as cardiovascular, emergency, pediatrics, psychiatry, oncology, dermatology, urology, and endocrinology diseases. The company markets its products through sales professionals to hospitals and physicians across the US. Arbor is headquartered in Atlanta, Georgia, the US.

Arbor Pharmaceuticals LLC-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deal Details 11

Asset Purchase 11

Arbor Pharma To Acquire US Rights For Gliadel Wafer From Eisai 11

Venture Financing 13

XenoPort Raises USD20 Million in Venture Financing 13

Private Equity 14

KKR to Acquire Minority Stake in Arbor Pharma 14

Partnerships 15

Debiopharm Enters into Distribution Agreement with Arbor Pharma 15

Licensing Agreements 16

Dr. Reddy's Labs Enters into Licensing Agreement with XenoPort for XP23829 16

Reckitt Benckiser Pharma Enters Into Licensing Agreement With XenoPort For Arbaclofen Placarbil 17

Takeda Pharma Enters Into Licensing Agreement With Arbor Pharma For Edarbi And Edarbyclor 18

Equity Offering 19

XenoPort Files Shelf Registration Statement for Public Offering of Shares For USD150 Million 19

XenoPort Completes Public Offering Of Shares For USD 85.8 Million 20

XenoPort Completes Public Offering Of Common Stock For USD 46 Million 21

Debt Offering 22

XenoPort Raises USD115 Million in Private Placement of 2.5% Notes Due 2022 22

Acquisition 24

Arbor Pharma Acquires Shares of XenoPort in a Tender Offer 24

Arbor Pharmaceuticals LLC-Key Competitors 26

Arbor Pharmaceuticals LLC-Key Employees 27

Arbor Pharmaceuticals LLC-Locations And Subsidiaries 28

Head Office 28

Other Locations & Subsidiaries 28

Appendix 29

Methodology 29

About GlobalData 29

Contact Us 29

Disclaimer 29


List Of Figure

List of Figures

Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Key Facts 2

Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Arbor Pharmaceuticals LLC, Deals By Therapy Area, 2012 to YTD 2018 8

Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Arbor Pharma To Acquire US Rights For Gliadel Wafer From Eisai 11

XenoPort Raises USD20 Million in Venture Financing 13

KKR to Acquire Minority Stake in Arbor Pharma 14

Debiopharm Enters into Distribution Agreement with Arbor Pharma 15

Dr. Reddy's Labs Enters into Licensing Agreement with XenoPort for XP23829 16

Reckitt Benckiser Pharma Enters Into Licensing Agreement With XenoPort For Arbaclofen Placarbil 17

Takeda Pharma Enters Into Licensing Agreement With Arbor Pharma For Edarbi And Edarbyclor 18

XenoPort Files Shelf Registration Statement for Public Offering of Shares For USD150 Million 19

XenoPort Completes Public Offering Of Shares For USD 85.8 Million 20

XenoPort Completes Public Offering Of Common Stock For USD 46 Million 21

XenoPort Raises USD115 Million in Private Placement of 2.5% Notes Due 2022 22

Arbor Pharma Acquires Shares of XenoPort in a Tender Offer 24

Arbor Pharmaceuticals LLC, Key Competitors 26

Arbor Pharmaceuticals LLC, Key Employees 27

Arbor Pharmaceuticals LLC, Subsidiaries 28

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Arbor Pharmaceuticals LLC, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.